Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

In Vitro Characterization and Stability Profiles of Antibody-Fluorophore Conjugates Derived from Interchain Cysteine Cross-Linking or Lysine Bioconjugation.

Martin C, Brachet G, Colas C, Allard-Vannier E, Kizlik-Masson C, Esnault C, Respaud R, Denevault-Sabourin C, Chourpa I, Gouilleux-Gruart V, Viaud-Massuard MC, Joubert N.

Pharmaceuticals (Basel). 2019 Dec 2;12(4). pii: E176. doi: 10.3390/ph12040176.

2.

S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization.

Boutin JA, Bouillaud F, Janda E, Gacsalyi I, Guillaumet G, Hirsch EC, Kane DA, Nepveu F, Reybier K, Dupuis P, Bertrand M, Chhour M, Le Diguarher T, Antoine M, Brebner K, Da Costa H, Ducrot P, Giganti A, Goswami V, Guedouari H, Michel PP, Patel A, Paysant J, Stojko J, Viaud-Massuard MC, Ferry G.

Mol Pharmacol. 2019 Mar;95(3):269-285. doi: 10.1124/mol.118.114231. Epub 2018 Dec 19.

3.

Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.

Aubrey N, Allard-Vannier E, Martin C, Bryden F, Letast S, Colas C, Lakhrif Z, Collinet N, Dimier-Poisson I, Chourpa I, Viaud-Massuard MC, Joubert N.

Bioconjug Chem. 2018 Nov 21;29(11):3516-3521. doi: 10.1021/acs.bioconjchem.8b00668. Epub 2018 Oct 25.

PMID:
30352511
4.

Consequences of cathepsin C inactivation for membrane exposure of proteinase 3, the target antigen in autoimmune vasculitis.

Seren S, Rashed Abouzaid M, Eulenberg-Gustavus C, Hirschfeld J, Nasr Soliman H, Jerke U, N'Guessan K, Dallet-Choisy S, Lesner A, Lauritzen C, Schacher B, Eickholz P, Nagy N, Szell M, Croix C, Viaud-Massuard MC, Al Farraj Aldosari A, Ragunatha S, Ibrahim Mostafa M, Giampieri F, Battino M, Cornillier H, Lorette G, Stephan JL, Goizet C, Pedersen J, Gauthier F, Jenne DE, Marchand-Adam S, Chapple IL, Kettritz R, Korkmaz B.

J Biol Chem. 2018 Aug 10;293(32):12415-12428. doi: 10.1074/jbc.RA118.001922. Epub 2018 Jun 20.

5.

Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.

Oyallon B, Brachet-Botineau M, Logé C, Bonnet P, Souab M, Robert T, Ruchaud S, Bach S, Berthelot P, Gouilleux F, Viaud-Massuard MC, Denevault-Sabourin C.

Eur J Med Chem. 2018 Jun 25;154:101-109. doi: 10.1016/j.ejmech.2018.04.056. Epub 2018 May 11.

PMID:
29778892
6.

Synthesis of naphthyridin-2(1H)-one derivatives via ring expansion of 3-substituted-1H-pyrrolo[2,3-b]pyridin-2(3H)-one derivatives.

Croix C, Massip S, Viaud-Massuard MC.

Chem Commun (Camb). 2018 May 29;54(44):5538-5541. doi: 10.1039/c8cc01518j.

PMID:
29736506
7.

Impact of Site-Specific Conjugation of ScFv to Multifunctional Nanomedicines Using Second Generation Maleimide.

Hervé-Aubert K, Allard-Vannier E, Joubert N, Lakhrif Z, Alric C, Martin C, Viaud-Massuard MC, Dimier-Poisson I, Aubrey N, Chourpa I.

Bioconjug Chem. 2018 May 16;29(5):1553-1559. doi: 10.1021/acs.bioconjchem.8b00091. Epub 2018 Mar 23.

PMID:
29553717
8.

Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.

Bryden F, Martin C, Letast S, Lles E, Viéitez-Villemin I, Rousseau A, Colas C, Brachet-Botineau M, Allard-Vannier E, Larbouret C, Viaud-Massuard MC, Joubert N.

Org Biomol Chem. 2018 Mar 14;16(11):1882-1889. doi: 10.1039/c7ob02780j.

PMID:
29473076
9.

Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

Martin C, Kizlik-Masson C, Pèlegrin A, Watier H, Viaud-Massuard MC, Joubert N.

MAbs. 2018 Feb/Mar;10(2):210-221. doi: 10.1080/19420862.2017.1412130. Epub 2018 Jan 9.

10.

Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.

Joubert N, Denevault-Sabourin C, Bryden F, Viaud-Massuard MC.

Eur J Med Chem. 2017 Dec 15;142:393-415. doi: 10.1016/j.ejmech.2017.08.049. Epub 2017 Aug 23. Review.

PMID:
28911823
11.

New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias.

Juen L, Brachet-Botineau M, Parmenon C, Bourgeais J, Hérault O, Gouilleux F, Viaud-Massuard MC, Prié G.

J Med Chem. 2017 Jul 27;60(14):6119-6136. doi: 10.1021/acs.jmedchem.7b00369. Epub 2017 Jul 12.

PMID:
28654259
12.

Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases.

Guarino C, Hamon Y, Croix C, Lamort AS, Dallet-Choisy S, Marchand-Adam S, Lesner A, Baranek T, Viaud-Massuard MC, Lauritzen C, Pedersen J, Heuzé-Vourc'h N, Si-Tahar M, Fıratlı E, Jenne DE, Gauthier F, Horwitz MS, Borregaard N, Korkmaz B.

Biochem Pharmacol. 2017 May 1;131:52-67. doi: 10.1016/j.bcp.2017.02.009. Epub 2017 Feb 11.

PMID:
28193451
13.

Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro.

Brachet G, Respaud R, Arnoult C, Henriquet C, Dhommée C, Viaud-Massuard MC, Heuze-Vourc'h N, Joubert N, Pugnière M, Gouilleux-Gruart V.

Mol Pharm. 2016 Apr 4;13(4):1405-12. doi: 10.1021/acs.molpharmaceut.6b00082. Epub 2016 Mar 1.

PMID:
26900766
14.

Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.

Baltus CB, Jorda R, Marot C, Berka K, Bazgier V, Kryštof V, Prié G, Viaud-Massuard MC.

Eur J Med Chem. 2016 Jan 27;108:701-719. doi: 10.1016/j.ejmech.2015.12.023. Epub 2015 Dec 19.

PMID:
26741853
15.

An ion-pairing, reversed-phase liquid chromatography method to assess the cross-contamination of cancer chemotherapy infusions prepared in a dual-operator aseptic isolator.

Brachet G, Bruno C, Boulay D, Tournamille JF, Gyan E, Viaud-Massuard MC, Respaud R.

Drug Test Anal. 2016 Sep;8(9):985-90. doi: 10.1002/dta.1902. Epub 2015 Oct 20.

PMID:
26480955
16.

Palladium-Catalyzed Amination of N-Free 2-Chloro-7-azaindole.

Plas A, Martin C, Joubert N, Viaud-Massuard MC.

Org Lett. 2015 Oct 2;17(19):4710-3. doi: 10.1021/acs.orglett.5b02173.

PMID:
26387551
17.

Correction to Rhodium-Catalyzed 1,4-Addition of Arylboronic Acids to 3-Benzylidene-1H-pyrrolo[2,3-b]pyridin-2(3H)-one Derivatives.

Croix C, Prié G, Chaulet C, Viaud-Massuard MC.

J Org Chem. 2015 Jun 5;80(11):5999. doi: 10.1021/acs.joc.5b00791. Epub 2015 May 11. No abstract available.

PMID:
25961809
18.

Rhodium-catalyzed 1,4-addition of arylboronic acids to 3-benzylidene-1H-pyrrolo[2,3-b]pyridin-2(3H)-one derivatives.

Croix C, Prié G, Chaulet C, Viaud-Massuard MC.

J Org Chem. 2015 Mar 20;80(6):3264-9. doi: 10.1021/jo502784h. Epub 2015 Mar 2. Erratum in: J Org Chem. 2015 Jun 5;80(11):5999.

PMID:
25689109
19.

Effect of formulation on the stability and aerosol performance of a nebulized antibody.

Respaud R, Marchand D, Parent C, Pelat T, Thullier P, Tournamille JF, Viaud-Massuard MC, Diot P, Si-Tahar M, Vecellio L, Heuzé-Vourc'h N.

MAbs. 2014;6(5):1347-55. doi: 10.4161/mabs.29938. Epub 2014 Oct 30.

20.

Computer-assisted management of unconsumed drugs as a cost-containment strategy in oncology.

Respaud R, Tournamille JF, Saintenoy G, Linassier C, Elfakir C, Viaud-Massuard MC, Antier D.

Int J Clin Pharm. 2014 Oct;36(5):892-5. doi: 10.1007/s11096-014-9974-1. Epub 2014 Jul 13.

PMID:
25022715
21.

Implementation study of patient-ready syringes containing 25 mg/mL methotrexate solution for use in treating ectopic pregnancy.

Respaud R, Gaudy AS, Arlicot C, Tournamille JF, Viaud-Massuard MC, Elfakir C, Antier D.

Biomed Res Int. 2014;2014:689308. doi: 10.1155/2014/689308. Epub 2014 May 12.

22.

A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids.

Respaud R, Quenum L, Plichon C, Tournamille JF, Gyan E, Antier D, Viaud-Massuard MC.

J Pharm Biomed Anal. 2013 Sep;83:164-70. doi: 10.1016/j.jpba.2013.05.007. Epub 2013 May 16.

PMID:
23747490
23.

Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Korkmaz B, Lesner A, Letast S, Mahdi YK, Jourdan ML, Dallet-Choisy S, Marchand-Adam S, Kellenberger C, Viaud-Massuard MC, Jenne DE, Gauthier F.

Semin Immunopathol. 2013 Jul;35(4):411-21. doi: 10.1007/s00281-013-0362-z. Epub 2013 Feb 6. Review.

PMID:
23385856
24.

Selective inhibitors of human neutrophil proteinase 3.

Korkmaz B, Kellenberger C, Viaud-Massuard MC, Gauthier F.

Curr Pharm Des. 2013;19(6):966-76. Review.

PMID:
23016687
25.

A selective reversible azapeptide inhibitor of human neutrophil proteinase 3 derived from a high affinity FRET substrate.

Epinette C, Croix C, Jaquillard L, Marchand-Adam S, Kellenberger C, Lalmanach G, Cadene M, Viaud-Massuard MC, Gauthier F, Korkmaz B.

Biochem Pharmacol. 2012 Mar 15;83(6):788-96. doi: 10.1016/j.bcp.2011.12.023. Epub 2011 Dec 24.

PMID:
22209715
26.

Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors.

Chaulet C, Croix C, Alagille D, Normand S, Delwail A, Favot L, Lecron JC, Viaud-Massuard MC.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):1019-22. doi: 10.1016/j.bmcl.2010.12.031. Epub 2010 Dec 10.

PMID:
21215621
28.

4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.

Parmenon C, Guillard J, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Dacquet C, Ktorza A, Viaud-Massuard MC.

Bioorg Med Chem Lett. 2009 May 15;19(10):2683-7. doi: 10.1016/j.bmcl.2009.03.143. Epub 2009 Apr 1.

PMID:
19376700
29.

First Mariner Mos1 transposase inhibitors.

Bouchet N, Bischerour J, Germon S, Guillard J, Dubernet M, Viaud-Massuard MC, Delelis O, Ryabinin V, Bigot Y, Augé-Gouillou C.

Mini Rev Med Chem. 2009 Apr;9(4):431-9. Review.

PMID:
19356121
30.

4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.

Parmenon C, Guillard J, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Dacquet C, Ktorza A, Viaud-Massuard MC.

Bioorg Med Chem Lett. 2008 Mar 1;18(5):1617-22. doi: 10.1016/j.bmcl.2008.01.067. Epub 2008 Jan 19.

PMID:
18255290
31.

Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.

Letellier MA, Guillard J, Caignard DH, Ferry G, Boutin JA, Viaud-Massuard MC.

Eur J Med Chem. 2008 Aug;43(8):1730-6. doi: 10.1016/j.ejmech.2007.11.010. Epub 2007 Nov 23.

PMID:
18164518
32.

Synthesis and biological evaluation of 7-azaindole derivatives, synthetic cytokinin analogues.

Guillard J, Decrop M, Gallay N, Espanel C, Boissier E, Herault O, Viaud-Massuard MC.

Bioorg Med Chem Lett. 2007 Apr 1;17(7):1934-7. Epub 2007 Jan 19.

PMID:
17300934
33.

Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.

Mailliet F, Ferry G, Vella F, Berger S, Cogé F, Chomarat P, Mallet C, Guénin SP, Guillaumet G, Viaud-Massuard MC, Yous S, Delagrange P, Boutin JA.

Biochem Pharmacol. 2005 Dec 19;71(1-2):74-88. Epub 2005 Nov 15.

PMID:
16293234
34.

Fosmidomycin analogues as inhibitors of monoterpenoid indole alkaloid production in Catharanthus roseus cells.

Mincheva Z, Courtois M, Andreu F, Rideau M, Viaud-Massuard MC.

Phytochemistry. 2005 Aug;66(15):1797-803.

PMID:
16054176
35.

Synthesis and biological evaluation with plant cells of new fosmidomycin analogues containing a benzoxazolone or oxazolopyridinone ring.

Courtois M, Mincheva Z, Andreu F, Rideau M, Viaud-Massuard MC.

J Enzyme Inhib Med Chem. 2004 Dec;19(6):559-65.

PMID:
15662959
36.

Design and synthesis of indole and tetrahydroisoquinoline hydantoin derivatives as human chymase inhibitors.

Alagille D, Pfeiffer B, Scalbert E, Ferry G, Boutin JA, Renard P, Viaud-Massuard MC.

J Enzyme Inhib Med Chem. 2004 Apr;19(2):137-43.

PMID:
15449728
37.

Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.

Larraya C, Guillard J, Renard P, Audinot V, Boutin JA, Delagrange P, Bennejean C, Viaud-Massuard MC.

Eur J Med Chem. 2004 Jun;39(6):515-26.

PMID:
15183910
38.

Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors.

Mailliet F, Audinot V, Malpaux B, Bonnaud A, Delagrange P, Migaud M, Barrett P, Viaud-Massuard MC, Lesieur D, Lefoulon F, Renard P, Boutin JA.

Biochem Pharmacol. 2004 Feb 15;67(4):667-77.

PMID:
14757166
39.

One-pot synthesis of functionalized 4,5-dihydroisoxazole derivatives via nitrile oxides and biological evaluation with plant cells.

Mincheva Z, Courtois M, Crèche J, Rideau M, Viaud-Massuard MC.

Bioorg Med Chem. 2004 Jan 2;12(1):191-7.

PMID:
14697784
40.

Synthesis of 3-aminochroman derivatives by radical cyclization.

Pavé G, Usse-Versluys S, Viaud-Massuard MC, Guillaumet G.

Org Lett. 2003 Nov 13;5(23):4253-6.

PMID:
14601973
41.

Enantioselective synthesis of spirocyclic aminochroman derivatives according to the CN(R,S) strategy.

Pavé G, Léger JM, Jarry C, Viaud-Massuard MC, Guillaumet G.

J Org Chem. 2003 Feb 21;68(4):1401-8.

PMID:
12585880

Supplemental Content

Loading ...
Support Center